NSG 5240 Midterm Focus Sheet | Fall 2025/2026 Complete Q&A
Update | South College
Dominate your advanced nursing pharmacology exam with this comprehensive midterm focus
sheet tailored specifically to the South College NSG 5240 curriculum. This premium study bank
features a presentation-ready layout with the correct answers highlighted in bold italics along
with exhaustive, evidence-based clinical rationales for every scenario. Designed with clean spacing
between items to maximize readability, this high-converting resource is your key to mastering complex
pharmacodynamics, receptor mechanisms, and safe prescribing guidelines.
Question 1
A nurse practitioner is adjusting the medication regimen for a patient with chronic kidney
disease (CKD) Stage 4. Which pharmacokinetic parameter is most critical to evaluate
when determining the dosage of a hydrophilic drug that is primarily eliminated by the
kidneys?
A) Phase II conjugation rate
B) Volume of distribution (Vd)
C) Glomerular filtration rate (GFR)
D) Hepatic first-pass metabolism
Correct Answer: C
Rationale: Hydrophilic (water-soluble) drugs are primarily excreted unchanged by the
kidneys. In a patient with advanced chronic kidney disease, a reduced glomerular
filtration rate (GFR) directly decreases drug clearance, leading to accumulation and
toxic plasma levels if the dose or frequency is not reduced. Phase II conjugation and
hepatic first-pass metabolism relate to liver clearance, which is less critical for purely
water-soluble drugs.
Question 2
An older adult patient is prescribed an administrative regimen of a highly lipid-soluble
medication. How does the age-related change in body composition affect the half-life
(\(t_{1/2}\)) of this drug?
A) The half-life decreases due to decreased body fat.
B) The half-life increases due to increased total body fat percentage.
C) The half-life remains unchanged because total body water decreases.
D) The half-life decreases due to a baseline rise in serum albumin.
Correct Answer: B
Rationale: Geriatric patients naturally experience an increase in adipose tissue (fat
percentage) and a decrease in total body water. Highly lipid-soluble drugs distribute
,widely into this expanded fat compartment, increasing their volume of distribution (Vd)
and prolonging their elimination half-life (\(t_{1/2}\)), which increases the risk of
prolonged drug effects or toxicity.
Question 3
A patient is initiated on warfarin therapy, which is known to be a highly protein-bound
drug (99%). Two weeks later, the patient is prescribed an additional drug that has a
stronger affinity for the same albumin binding sites. What clinical effect should the
practitioner anticipate?
A) A decrease in the therapeutic efficacy of warfarin.
B) A rapid decrease in the patient's International Normalized Ratio (INR).
C) An increase in the concentration of free, unbound warfarin in the plasma.
D) An increase in the clearance of the new drug due to competitive inhibition.
Correct Answer: C
Rationale: When a highly protein-bound drug is displaced from albumin binding sites by
another agent with a higher affinity, the concentration of active, free (unbound) drug in
the plasma increases immediately. For warfarin, an increase in free drug enhances its
anticoagulant effect, rising the INR and increasing the risk of major hemorrhage.
Question 4
A patient who is an ultra-rapid metabolizer of the Cytochrome P450 enzyme CYP2D6 is
prescribed codeine for pain management. What is the primary safety concern regarding
this patient's metabolism?
A) The patient will experience no pain relief due to rapid clearance of codeine.
B) The patient will accumulate toxic levels of codeine, causing severe liver necrosis.
C) The patient will rapidly convert codeine into high concentrations of morphine, risking
respiratory depression.
D) The patient will experience an immediate allergic reaction due to enzyme induction.
Correct Answer: C
Rationale: Codeine is a prodrug that must be metabolized by the CYP2D6 enzyme into
its active form, morphine, to provide analgesia. An ultra-rapid metabolizer processes
codeine into morphine far more rapidly and extensively than normal, resulting in toxic
plasma levels of morphine that can cause fatal respiratory depression.
Question 5
A practitioner notes that a drug acts as a potent Cytochrome P450 CYP3A4 enzyme
inhibitor. The patient is also taking simvastatin, a known CYP3A4 substrate. What
complication can occur if these drugs are administered concurrently?
A) Subtherapeutic simvastatin levels leading to a stroke.
B) Accelerated clearance of simvastatin through the bowel.
C) Falsely decreased serum creatinine levels.
D) Markedly elevated plasma levels of simvastatin, increasing the risk of
rhabdomyolysis.
,Correct Answer: D
Rationale: Inhibiting the CYP3A4 enzyme slows the metabolism of its substrates.
Because simvastatin relies on CYP3A4 for clearance, co-administering an inhibitor
causes the statin to accumulate to dangerous levels in the plasma, significantly
increasing the risk of statin-induced myopathy and life-threatening rhabdomyolysis.
Question 6
Which pharmacological term describes the fraction of an administered drug dose that
reaches the systemic circulation in an unchanged, active form?
A) Bioavailability
B) Clearance
C) Steady-state concentration
D) Therapeutic index
Correct Answer: A
Rationale: Bioavailability refers to the percentage of an administered drug dose that
enters systemic circulation unchanged. Intravenous drugs have 100% bioavailability,
whereas oral medications have lower bioavailability due to incomplete absorption and
hepatic first-pass metabolism.
Question 7
A nurse practitioner is prescribing a medication with a narrow therapeutic index (TI).
Which statement best guides the clinical management of this medication?
A) The drug can be safely administered without monitoring because its toxic dose is
extremely high.
B) The difference between the effective therapeutic dose and the toxic dose is very
small, requiring routine serum drug level monitoring.
C) The drug has a long half-life and will reach a steady state within a single dosing
interval.
D) The drug works purely via physical mechanisms and does not bind to cellular
receptors.
Correct Answer: B
Rationale: A narrow therapeutic index means that the margin of safety between the
effective concentration and the minimum toxic concentration is slim. Small changes in
plasma levels can cause subtherapeutic failure or severe toxic reactions, making routine
serum drug monitoring essential.
Question 8
A patient with severe decompensated heart failure has a markedly reduced cardiac
output. Which phase of pharmacokinetics will be altered most immediately by this
pathophysiology?
A) Gastrointestinal absorption rate
B) Distribution to target peripheral tissues
, C) Renal tubular secretion capacity
D) Phase I oxidation reactions
Correct Answer: B
Rationale: Distribution is the process of a drug moving throughout body fluids and
tissues. It depends heavily on perfusion and blood flow. Reduced cardiac output directly
impairs blood delivery to peripheral tissues, altering and delaying drug distribution to
target organs.
Question 9
A patient requires an immediate therapeutic effect from an antibiotic with a very long
half-life. Which dosing strategy should the nurse practitioner implement?
A) Administer an initial loading dose followed by standard maintenance doses.
B) Administer small maintenance doses frequently over 48 hours.
C) Withhold the drug until the patient's baseline creatinine clearance increases.
D) Administer the medication alongside a potent loop diuretic.
Correct Answer: A
Rationale: A loading dose is a large initial dose given to rapidly achieve the target
therapeutic plasma concentration. This strategy is vital for drugs with long half-lives,
which would otherwise take several days or weeks (roughly 4 to 5 half-lives) to reach a
steady-state therapeutic level on maintenance dosing alone.
Question 10
Which type of drug binds to a specific cell receptor and activates it to produce a
maximal functional response that mimics endogenous signaling molecules?
A) Competitive antagonist
B) Full agonist
C) Inverse agonist
D) Non-competitive antagonist
Correct Answer: B
Rationale: A full agonist binds to a receptor and induces a conformational change that
produces a maximal biological response, fully mimicking the body's natural signaling
molecules. Antagonists bind to receptors but block activation.
Question 11
A patient is prescribed a new transdermal patch for chronic pain management. Which
dermal characteristic will significantly increase the systemic absorption rate of this
topical patch?
A) Applying the patch over thick, calloused skin surfaces.
B) Applying the patch to a highly vascularized area with compromised skin integrity or
inflammation.
C) Keeping the patch completely cold and isolated from body heat.
D) Choosing a site with a thick subcutaneous fat layer.
Update | South College
Dominate your advanced nursing pharmacology exam with this comprehensive midterm focus
sheet tailored specifically to the South College NSG 5240 curriculum. This premium study bank
features a presentation-ready layout with the correct answers highlighted in bold italics along
with exhaustive, evidence-based clinical rationales for every scenario. Designed with clean spacing
between items to maximize readability, this high-converting resource is your key to mastering complex
pharmacodynamics, receptor mechanisms, and safe prescribing guidelines.
Question 1
A nurse practitioner is adjusting the medication regimen for a patient with chronic kidney
disease (CKD) Stage 4. Which pharmacokinetic parameter is most critical to evaluate
when determining the dosage of a hydrophilic drug that is primarily eliminated by the
kidneys?
A) Phase II conjugation rate
B) Volume of distribution (Vd)
C) Glomerular filtration rate (GFR)
D) Hepatic first-pass metabolism
Correct Answer: C
Rationale: Hydrophilic (water-soluble) drugs are primarily excreted unchanged by the
kidneys. In a patient with advanced chronic kidney disease, a reduced glomerular
filtration rate (GFR) directly decreases drug clearance, leading to accumulation and
toxic plasma levels if the dose or frequency is not reduced. Phase II conjugation and
hepatic first-pass metabolism relate to liver clearance, which is less critical for purely
water-soluble drugs.
Question 2
An older adult patient is prescribed an administrative regimen of a highly lipid-soluble
medication. How does the age-related change in body composition affect the half-life
(\(t_{1/2}\)) of this drug?
A) The half-life decreases due to decreased body fat.
B) The half-life increases due to increased total body fat percentage.
C) The half-life remains unchanged because total body water decreases.
D) The half-life decreases due to a baseline rise in serum albumin.
Correct Answer: B
Rationale: Geriatric patients naturally experience an increase in adipose tissue (fat
percentage) and a decrease in total body water. Highly lipid-soluble drugs distribute
,widely into this expanded fat compartment, increasing their volume of distribution (Vd)
and prolonging their elimination half-life (\(t_{1/2}\)), which increases the risk of
prolonged drug effects or toxicity.
Question 3
A patient is initiated on warfarin therapy, which is known to be a highly protein-bound
drug (99%). Two weeks later, the patient is prescribed an additional drug that has a
stronger affinity for the same albumin binding sites. What clinical effect should the
practitioner anticipate?
A) A decrease in the therapeutic efficacy of warfarin.
B) A rapid decrease in the patient's International Normalized Ratio (INR).
C) An increase in the concentration of free, unbound warfarin in the plasma.
D) An increase in the clearance of the new drug due to competitive inhibition.
Correct Answer: C
Rationale: When a highly protein-bound drug is displaced from albumin binding sites by
another agent with a higher affinity, the concentration of active, free (unbound) drug in
the plasma increases immediately. For warfarin, an increase in free drug enhances its
anticoagulant effect, rising the INR and increasing the risk of major hemorrhage.
Question 4
A patient who is an ultra-rapid metabolizer of the Cytochrome P450 enzyme CYP2D6 is
prescribed codeine for pain management. What is the primary safety concern regarding
this patient's metabolism?
A) The patient will experience no pain relief due to rapid clearance of codeine.
B) The patient will accumulate toxic levels of codeine, causing severe liver necrosis.
C) The patient will rapidly convert codeine into high concentrations of morphine, risking
respiratory depression.
D) The patient will experience an immediate allergic reaction due to enzyme induction.
Correct Answer: C
Rationale: Codeine is a prodrug that must be metabolized by the CYP2D6 enzyme into
its active form, morphine, to provide analgesia. An ultra-rapid metabolizer processes
codeine into morphine far more rapidly and extensively than normal, resulting in toxic
plasma levels of morphine that can cause fatal respiratory depression.
Question 5
A practitioner notes that a drug acts as a potent Cytochrome P450 CYP3A4 enzyme
inhibitor. The patient is also taking simvastatin, a known CYP3A4 substrate. What
complication can occur if these drugs are administered concurrently?
A) Subtherapeutic simvastatin levels leading to a stroke.
B) Accelerated clearance of simvastatin through the bowel.
C) Falsely decreased serum creatinine levels.
D) Markedly elevated plasma levels of simvastatin, increasing the risk of
rhabdomyolysis.
,Correct Answer: D
Rationale: Inhibiting the CYP3A4 enzyme slows the metabolism of its substrates.
Because simvastatin relies on CYP3A4 for clearance, co-administering an inhibitor
causes the statin to accumulate to dangerous levels in the plasma, significantly
increasing the risk of statin-induced myopathy and life-threatening rhabdomyolysis.
Question 6
Which pharmacological term describes the fraction of an administered drug dose that
reaches the systemic circulation in an unchanged, active form?
A) Bioavailability
B) Clearance
C) Steady-state concentration
D) Therapeutic index
Correct Answer: A
Rationale: Bioavailability refers to the percentage of an administered drug dose that
enters systemic circulation unchanged. Intravenous drugs have 100% bioavailability,
whereas oral medications have lower bioavailability due to incomplete absorption and
hepatic first-pass metabolism.
Question 7
A nurse practitioner is prescribing a medication with a narrow therapeutic index (TI).
Which statement best guides the clinical management of this medication?
A) The drug can be safely administered without monitoring because its toxic dose is
extremely high.
B) The difference between the effective therapeutic dose and the toxic dose is very
small, requiring routine serum drug level monitoring.
C) The drug has a long half-life and will reach a steady state within a single dosing
interval.
D) The drug works purely via physical mechanisms and does not bind to cellular
receptors.
Correct Answer: B
Rationale: A narrow therapeutic index means that the margin of safety between the
effective concentration and the minimum toxic concentration is slim. Small changes in
plasma levels can cause subtherapeutic failure or severe toxic reactions, making routine
serum drug monitoring essential.
Question 8
A patient with severe decompensated heart failure has a markedly reduced cardiac
output. Which phase of pharmacokinetics will be altered most immediately by this
pathophysiology?
A) Gastrointestinal absorption rate
B) Distribution to target peripheral tissues
, C) Renal tubular secretion capacity
D) Phase I oxidation reactions
Correct Answer: B
Rationale: Distribution is the process of a drug moving throughout body fluids and
tissues. It depends heavily on perfusion and blood flow. Reduced cardiac output directly
impairs blood delivery to peripheral tissues, altering and delaying drug distribution to
target organs.
Question 9
A patient requires an immediate therapeutic effect from an antibiotic with a very long
half-life. Which dosing strategy should the nurse practitioner implement?
A) Administer an initial loading dose followed by standard maintenance doses.
B) Administer small maintenance doses frequently over 48 hours.
C) Withhold the drug until the patient's baseline creatinine clearance increases.
D) Administer the medication alongside a potent loop diuretic.
Correct Answer: A
Rationale: A loading dose is a large initial dose given to rapidly achieve the target
therapeutic plasma concentration. This strategy is vital for drugs with long half-lives,
which would otherwise take several days or weeks (roughly 4 to 5 half-lives) to reach a
steady-state therapeutic level on maintenance dosing alone.
Question 10
Which type of drug binds to a specific cell receptor and activates it to produce a
maximal functional response that mimics endogenous signaling molecules?
A) Competitive antagonist
B) Full agonist
C) Inverse agonist
D) Non-competitive antagonist
Correct Answer: B
Rationale: A full agonist binds to a receptor and induces a conformational change that
produces a maximal biological response, fully mimicking the body's natural signaling
molecules. Antagonists bind to receptors but block activation.
Question 11
A patient is prescribed a new transdermal patch for chronic pain management. Which
dermal characteristic will significantly increase the systemic absorption rate of this
topical patch?
A) Applying the patch over thick, calloused skin surfaces.
B) Applying the patch to a highly vascularized area with compromised skin integrity or
inflammation.
C) Keeping the patch completely cold and isolated from body heat.
D) Choosing a site with a thick subcutaneous fat layer.
